Dose rate measurements from radiopharmaceuticals: implications for nuclear medicine staff and for children with radioactive parents

Following the introduction of a number of radiopharmaceuticals, we assessed the dose received by staff working in the nuclear medicine department and also by children who may be in close contact with a radioactive parent. We measured departure dose rates (microSv.h-1) at distances of 0.1, 0.5 and 1.0 m from the skin surface at the level of the thyroid, chest and bladder of patients undergoing the following nuclear medicine procedures: MUGA scans using 99Tcm-labelled red blood cells, myocardial perfusion scans using 99Tcm-labelled radiopharmaceuticals, lymphoscintigraphy using colloidal 99Tcm (Re) sulphide, bone scans using 99Tcm-labelled oxidronate, 111In-octreotide scans, 111In-labelled leukocyte studies and cardiac reinjection studies using 201Tl. The maximum dose rates at 0.1 m were those from MUGA studies (167.3 microSv.h-1) and myocardial perfusion studies (one-day protocol = 391.7 microSv.h-1, two-day protocol = 121.8 microSv.h-1). The implications of these dose rates on both technical and nursing staff are assessed. Also, the dose received by an infant in close contact with a parent following a nuclear medicine investigation was estimated.     

Radiation dose rates from paediatric patients undergoing 99Tcm investigations.

Infants or children undergoing nuclear medicine investigations may subsequently come into close contact with nurses or parents responsible for their care. In order to estimate the radiation dose to these individuals, and to formulate appropriate recommendations, dose rates were measured at distances of 0.1, 0.5 and 1.0 m from 148 paediatric patients who had undergone one of 12 99Tcm studies. The maximum dose rates of 70, 14 and 5 microSv h-1 at these distances were not greater than the corresponding maximum values found in an earlier study of adult patients. However, the maximum dose rates per unit activity of 0.5, 0.2 and 0.1 microSv h-1 MBq-1 were greater than the corresponding maximum 99Tcm adult values, consistent with a general increase of dose rate per unit activity with decrease of body weight observed in the paediatric measurements. A parent caring for and feeding a young infant is most unlikely to receive a dose equivalent of 1 mSv, and a nurse attending to one young radioactive patient is most unlikely to receive a dose equivalent in a working day of 60 microSv. The data obtained should allow radiation doses to be estimated and appropriate recommendations to be formulated for other circumstances, including any future legislative changes in dose limits or derived levels.     

99Tcm and 111In leucocyte scintigraphy in inflammatory bowel disease.

A comparative study of 99Tcm-hexamethylpropyleneamine oxime (HMPAO) and 111In leucocyte scintigraphy was performed in inflammatory bowel disease. Two hundred and thirty-four patients were studied, 146 had 99Tcm-HMPAO, 82 had 111In and six had both. The sensitivity, specificity and accuracy of the 99Tcm leucocyte scan were 96, 97 and 97%, respectively, and 96, 97 and 97%, respectively, for the 111In leucocyte scan. 99Tcm-HMPAO leucocytes demonstrated similar diagnostic accuracy to 111In-labelled leucocytes with improved image quality and reduced radiation dose.     

Estimation of close contact doses to young infants from surface dose rates on radioactive adults

A general method is given to estimate the dose to an infant held in close contact to a radioactive parent. Calculated values of effective exposure times are given for various radiopharmaceuticals corresponding to a simplified sequence of periods of close contact. When multiplied by a measurement of the dose rate on the surface of an adult, these times can be used to give a quick upper estimate of a close contact dose. This allows a decision whether it is necessary to issue instructions for restricting the duration of close contact to an adult patient, before the patient leaves a nuclear medicine department. Estimates of close contact dose have been made from measurements of surface dose rate using these effective exposure times. Doses to infants from adults who have undergone diagnostic radiopharmaceutical procedures can be kept below 1 mSv without imposing restrictions in close contact. A close contact dose of 1 mSv will be exceeded by activities of 131-I iodide greater than 112 MBq.     

核医学工作人员和受检者辐射防护现状

诊断核医学使用的放射性药物具有电离辐射效应,有可能损害核医学工作人员和受检者的健康或危及生命。笔者介绍了国内外诊断核医学近年来的发展趋势,并对核医学工作人员和受检者在不同检查项目中的辐射剂量进行重点分析,评估他们的辐射防护状况。笔者分析了近年来核医学辐射防护领域的研究,结果表明在采取有效防护措施的情况下,核医学工作人员的年有效剂量低于放射性工作人员的年剂量限值。受检者接受SPECT检查所致的辐射剂量主要来自99Tcm标记的单光子放射性药物,接受PET/CT检查所致的辐射剂量绝大部分来自CT扫描,所以选择合适的放射性药物活度和CT采集条件可以显著降低受检者的辐射剂量。     

99Tcm-labelled HSA-nanocolloid versus 111In oxine-labelled granulocytes in detecting skeletal septic process

Fifty-seven investigations of the skeletal system were performed on 54 patients, using a 99Tcm-labelled nanometer-sized HSA colloid in a crossover comparison with 111In oxine-labelled granulocytes for the detection of sites of infection. The findings were in agreement in 55 out of 57 investigations (96.5%). Based on 44 studies in which a final clinical diagnosis was obtained, both methods were found to display the same specificity (93%), whilst the sensitivity of 99Tcm nanocolloid scintigraphy (87%) was slightly higher than that obtained with 111In leucocyte scintigraphy (81%). In our opinion, 99Tcm nanocolloid is easier to use and the total duration of the investigation is considerably shorter. The use of 99Tcm is scintigraphically more advantageous and, with the dosage required, the absorbed radiation dose to the red bone marrow is three times lower than with 111In granulocytes. For the detection and therapy monitoring of osteomyelitis, as well as for the investigation of arthroplasties suspected of infective loosening, we consider scintigraphy with 99Tcm nanocolloid to be equivalent to leucocyte scintigraphy. Identical findings were obtained with both tracers in suspected spondylodiscitis.     

Radiation dose rates from patients undergoing PET: implications for technologists and waiting areas

Increasingly hospitals are showing an interest in developing their imaging services to include positron emission tomography (PET). There is therefore a need to be aware of the radiation doses to critical groups. To assess the effective whole-body dose received by technologists within our dedicated PET centre, each staff member was issued with a dose rate meter, and was instructed to record the time spent in contact with any radioactive source, the dose received per working day and the daily injected activity. On average each technologist administered 831 MBq per day. The mean whole-body dose per MBq injected was 0.02 microSv/MBq(-1). The average time of close contact (<2.0 m) with a radioactive source per day was 32 min. The average effective dose per minute close contact was 0.5 microSv/min(-1), which resulted in a mean daily effective dose of 14.4 microSv. No technologist received greater than 60 microSv (the current UK limit for non-classified workers) in any one day, and in general doses received were less than 24 microSv, the daily dose corresponding to the proposed new annual limit for non-classified workers of 6.0 mSv per annum. However, we recognise that the layout of nuclear medicine departments will not mirror our own. We therefore measured the instantaneous dose rates at 0.1, 0.5, 1.0 and 2.0 m from the mid-thorax on 115 patients immediately after injection, to provide estimates of the likely effective doses that might be received by technologists operating dual-headed coincidence detection systems, and others coming into contact in the waiting room with patients who have been injected with fluorine-18 fluorodeoxyglucose. The mean (95th percentile) dose rates measured at the four aforementioned distances were 391.7 (549.5), 127.0 (199.8), 45.3 (70.0) and 17.1 (30.0) microSv/h(-1), respectively. A number of situations have been modelled showing that, with correct planning, FDG studies should not significantly increase the effective doses to technologists. However, one possible area of concern is that, depending on the number of patients in a waiting area at any one time, accompanying persons may approach the limits set by the new UK IRR 1999 regulations for members of the public.     

99Tcm-MDP, 67Ga-citrate and 111In-leucocytes for detecting prosthetic hip infection

An assessment was made of the roles of 99Tcm-MDP, 67Ga-citrate and 111In-leucocytes in identifying infected hip prostheses. Fifty painful prosthetic hips were investigated with a 99Tcm-MDP bone scan and an 111In-labelled leucocyte scan (ILLS). In 32 cases, a 67Ga-citrate scan was also performed. Normal or focal MDP uptake was obtained only in uninfected hips. Diffuse uptake of MDP was obtained only in infected hips and in one case of non-septic synovitis which also produced a false positive ILLS. A focal MDP uptake superimposed on a diffuse pattern was obtained in both infected and uninfected hips. The ILLS was abnormal in eight out of 11 cases of infection and in two out of 39 cases without infection. The 67Ga scan was abnormal in five out of six cases of infection and in five out of 26 cases without infection. It was concluded that a 99Tcm bone scan should be performed first on a painful prosthetic hip, and that for detecting infection, an ILLS was more specific but less sensitive than a 67Ga-citrate scan.     

Breast milk activity during early lactation following maternal 99Tcm macroaggregated albumin lung perfusion scan

A breast feeding infant may receive a radiation dose from ingestion of breast milk following the administration of a radiopharmaceutical to the mother. The Administration of Radioactive Substances Advisory Committee recommendation to interrupt breast feeding may not necessarily apply in the period of early lactation when colostrum is being produced. Following a lung scan using 99Tcm macroaggregated albumin (MAA) on a patient approximately 15 h post partum, radioactivity within breast milk was measured. Milk was expressed approximately every 4 h during the day and samples were counted. The sample radioactivity concentration peaked at 15 h and decayed monoexponentially (half clearance time was approximately 4.8 h). The estimated effective dose to the infant from ingestion alone, had breast feeding not been interrupted, was approximately 0.02 mSv. These data suggest that interruption to breast feeding may not be necessary following administration of up to the diagnostic reference level of 99Tcm MAA during early lactation.     

Osteomyelitis

The use of 111In-labelled granulocyte scintigraphy is recognized as a reliable method for detecting osteomyelitis and has similar sensitivity and significantly increased specificity compared to bone scintigraphy and 67Ga studies. Recent published work using pure granulocytes labelled with 111In tropolonate to detect osteomyelitis resulted in sensitivity of 100% and specificity of 92%. 99Tcm as an alternative granulocyte label offers advantages of convenience, lower radiation dose and higher image resolution. We have scanned 20 patients with suspected osteomyelitis using autologous granulocytes labelled with 99Tcm hexamethylpropyleneamineoxime (HMPAO), 12 of whom had prosthetic joints. The scan results were correlated with clinical, radiographic, microbiological and histological findings. Sensitivity was 100% and specificity was 93% which compares favourably with results obtained using 111In-labelled granulocytes. We believe that labelled granulocyte scintigraphy is a useful investigation in the diagnosis of osteomyelitis and that 99Tcm HMPAO appears to be at least as useful as 111In as the labelling agent.     

核医学诊疗中患者内照射的研究进展

在核医学诊疗中,放射性核素不仅照射患者体内的靶器官,同时对其他正常的组织和器官也会产生照射。笔者介绍了国内外与核医学有关的人体辐射剂量模型发展趋势,重点针对核医学常用的3种放射性核素（18F、99Tcm、131I）标记的显像剂导致患者内照射剂量及其影响因素进行综述,为研究核医学诊疗患者内照射剂量与辐射防护工作提供参考。     

Pharmacokinetics, biodistribution and dosimetry of 99Tcm(V)DMSA in humans with squamous cell carcinoma

Technetium-99m (99Tcm)(V) dimercaptosuccinic acid (DMSA) is a new tumour imaging agent which has been used to evaluate squamous carcinoma (SCC) of the head and neck. This study evaluated the pharmacokinetics and biodistribution of 99Tcm(V)DMSA in patients with SCC and calculated the bone mass of a New Zealand White (NZW) rabbit. This data was then used to calculate the effective dose equivalent in man. A total of 16 patients were studied (5 with no tumour, 11 with tumour). 99Tcm(V)DMSA had a fast bi-exponential blood clearance in patients with no tumour (30 and 401 min) and patients with tumour (30 and 387 min) with no significant difference (p greater than 0.05) between the two groups. 99Tcm(V)DMSA had a fast cumulative urine excretion with mean half-times in non-tumour and tumour patients of 183 min and 244 min respectively. There was no significant difference (p greater than 0.05) between these two latter groups. The effective dose equivalent of 99Tcm(V)DMSA in man is 5.1 microSv/MBq.     

Large-body radiation doses following radioiodine therapy

In accordance with the recommendations of the International Radiological Protection Commission, the current maximum acceptable radiation dose limits for members of the public have been reduced to 1 mSv in the United States, Canada, and European Union countries including the United Kingdom. This has had a significant impact on radiation protection guidelines for contacts of patients treated with 131I. Many previous recommendations have relied upon models which may overestimate dose rates at short distances. We therefore undertook measurements of 131I dose rates using adult and infant phantoms that more accurately reflected true geometry. Effective dose calculations and patient contact restrictions were then derived from these direct dose measurements. Doses received by the adult phantom were measured at three distances (contact, 1.0 m, 2.0 m) and doses received by the infant phantom were measured at contact in two orientations (adult cradling infant over shoulder and at waist). The doses measured were significantly lower than previously predicted for the adult and infant phantom. Our measurements suggest that patient contact restrictions could be made less stringent than those currently in widespread use.     

99Tcm-HMPAO labelled leucocytes: comparison with 111In-tropolonate labelled granulocytes

The lipophilic complex, 99Tcm-hexamethylpropyleneamine oxime (HMPAO) is an efficient leucocyte label, and labels granulocytes with more stability than mononuclear leucocytes. The recovery of 99Tcm-HMPAO granulocytes, expressed as the percentage of injected granulocyte-associated activity circulating as granulocyte-associated activity 40-45 min after injection, was 37% (S.E. 3%), similar to the recovery of 111In-labelled granulocytes isolated and labelled in plasma using tropolone. The T1/2 of 99Tcm-HMPAO labelled granulocytes in blood was 4.4 h (S.E. 0.4 h), less than that of 111In-labelled granulocytes, although when a correction was made for 99Tcm elution, it was 6.4 h. The initial biodistribution of 99Tcm-labelled leucocytes was similar to 111In-labelled granulocytes, with a rapid initial lung transit, prominent splenic activity, bone marrow activity and minimal hepatic activity, although, unlike 111In, 99Tcm activity was also seen in urine, occasionally in the gallbladder, and, from about 4 h, consistently in the colon. Bone marrow activity was particularly prominent with 99Tcm. About 6% of 99Tcm was excreted in the faeces up to 48 h after injection, and about 17% in urine up to 24 h. The time-activity curves of reticuloendothelial activity up to 24 h were broadly similar for the two labelled cell preparations, and the differences that were observed can be explained on the basis of a higher rate of 99Tcm elution. Clinical information given by the two agents was similar in 27 of 30 patients who received both. Of the three who gave different information, one received 111In-labelled granulocytes which were considered to be functionally suboptimal and two, with inflammatory bowel disease, showed different distributions of abnormal bowel activity. We conclude that with respect to granulocyte kinetics and clinical data, 99Tcm-HMPAO labelled leucocytes are comparable with 111In-tropolonate labelled granulocytes.     

Occupational radiation dose associated with Rb-82 myocardial perfusion positron emission tomography imaging

BACKGROUND: We determined staff radiation dose during rest and stress rubidium 82 myocardial perfusion positron emission tomography (PET) imaging. METHODS AND RESULTS: Patients received 1,587 +/- 163 MBq (42.9 +/- 4.4 mCi) Rb-82 during rest or pharmacologic stress. A pressurized ion chamber was used to monitor radiation exposure in 50 examinations. For comparison, staff exposure during pharmacologic stress in 20 other patients receiving 1,204 +/- 55.5 MBq (32.54 +/- 1.5 mCi) technetium 99m 2-methoxy isobutyl isonitrile (MIBI) was measured. For Rb-82 infusion and PET acquisition, the mean dose was 0.45 +/- 0.25 microSv (0.045 +/- 0.025 mrem). Exposure for routine stress testing at variable distances from the patient was equivalent to background. Similar exposure for pharmacologic stress testing through 7 minutes after injection of Tc-99m MIBI at variable distances was 1.075 +/- 0.32 microSv (0.108 +/- 0.03 mrem). However, exposure for stress tests starting 7 minutes after Rb-82 infusion at 0.5 m was estimated at 0.4 microSv (0.04 mrem). To determine the potential radiation dose for those responding to a medical emergency or otherwise in close proximity to a patient, we measured the mean cumulative dose at 0.5 m from 0 to 7 minutes of Rb-82 infusion, which resulted in 19.1 +/- 5.8 microSv (1.9 +/- 0.58 mrem). CONCLUSIONS: Radiation doses for all tasks during routine Rb-82 stress-rest PET are lower than measured Tc-99m MIBI values. However, the radiation dose in close proximity to the patient during or immediately after Rb-82 infusion can be considerably higher, underscoring the need for strict attention to source distance and contact times.     

Dual radionuclide subtraction imaging of vertebral disc infection using an 111In-labelled leucocyte scan and a 99mTc-tin colloid scan

Interpretation of the posterior view of an 111In-labelled leucocyte scan is difficult when infection is suspected in that region of the spine overlaid by the left lobe of the liver. A case is reported of the successful localisation of infection in this region by combining an 111In-labelled leucocyte scan with a 99mTc-tin colloid scan in a dual radionuclide subtraction technique.     

The radiation dose to accompanying nurses, relatives and other patients in a nuclear medicine department waiting room

The radiation dose to accompanying nurses, relatives and other patients in a nuclear medicine department waiting room was assessed at 5 min intervals by observing the seating arrangement. The total radiation dose to each person was calculated, using fixed values of dose rate per 100 MBq activity for radionuclides, and applying the inverse square law. Radioactive decay and attenuation effects due to intervening persons were also taken into account. The median radiation doses to accompanying nurses, relatives and other patients were 2.3, 2.0 and 0.2 microSv with maximum values of 17, 33 and 5 microSv respectively. In all cases, the radiation dose received by patients was less than 0.2% of the radiation dose resulting from their own investigation. Also, the maximum radiation dose received by an accompanying nurse or friend was less than 1% of their appropriate annual dose limit. Similar values were obtained with calculations based on a 15 min time interval. The radiation doses received by those in a nuclear medicine department waiting room are small, and separate waiting room facilities for radioactive patients are unnecessary.     

Dose rates from patients having nuclear medicine investigations

Dose rates have been measured at 0.1 m, 0.5 m and 1.0 m from patients in a Nuclear Medicine Department. Data are presented for a variety of Nuclear Medicine procedures using doses of radiopharmaceuticals within the recommendations of the administration of Radioactive Substances Advisory Committee (ARSAC). The corresponding figures when the patient left the department, and the time average dose rate over the next 8 h were calculated. At 1.0 m the dose rates do not exceed 7.5 microSv h-1, and at 0.5 m the time average dose rate does not exceed 60 microSv h-1. Assuming that the nurse is as close to the patient as 0.1 m for 20 min in a working day, the accumulated dose over a working day would not exceed 60 microSv.     

Radiolabelled granulocytes in inflammatory bowel disease: diagnostic possibilities and clinical indications

Radiolabelled granulocytes in chronic inflammatory bowel diseases (CIBD) are able to diagnose the disease extent and assess the disease activity. It may be performed with 111In oxine- and 99Tcm hexamethylpropyleneamineoxime (HMPAO)-labelled cells. The granulocyte scan localizes inflamed bowel segments with an accuracy comparable with radiology and endoscopy including biopsy of the bowel (r = 0.95; P less than 0.001). The specificity of the scan for diseased segments is near 100%, the sensitivity 92%. A three-phase white blood cell scan (imaging: 0.5, 4, 20 h post injection) allows differentiation of diseased bowel segments from abscesses and fistulas. False positive results are possible in necrotic carcinomas. The 99Tcm HMPAO scan shows rapid renal and delayed biliary and intestinal excretion of tracer. In this way diagnostic problems arise in the small pelvis. Because of the intestinal and biliary excretion, early images should be obtained (0.5-2 h post injection). Later scans with 99Tcm HMPAO are of minor importance. The disease activity can very specifically be assessed by the determination of the percentage faecal 111In excretion (96 h faecal collection). Active and non-active diseases can be clearly differentiated. We found no correlation with the subjectively influenced Crohn's disease activity index (CDAI) (r = 0.25; P greater than 0.05), but good correlations with the Dutch Index (van Hees: r = 0.67), ESR (r = 0.69), serum albumin (r = -0.54) and orosomucoid (r = 0.65). The percentage faecal excretion correlates well with the histologically estimated leucocytic bowel infiltration. Because of the intestinal 99Tcm HMPAO excretion the determination of faecal excretion is pointless in 99Tcm studies.(ABSTRACT TRUNCATED AT 250 WORDS)     

Management of the helpless patient after radioiodine ablation therapy - are we being too strict?

BACKGROUND: A helpless patient was administered 1 GBq of I to ablate thyroid remnants post-thyroidectomy. The patient was quadriplegic, doubly incontinent and unable to swallow. Published data suggest that nursing staff may receive a total effective dose of 3400 microSv when dealing with such a patient for one 8 h shift per day for 7 days post-treatment. AIM: To quantify the effective doses received by nursing staff on dealing with a helpless patient undergoing radioiodine ablation therapy. METHODS: After intravenous administration of 131I, the whole-body doses received by nursing staff were measured using electronic personal dosemeters for 7 days. The nursing staff recorded the times spent in contact with the patient and the activities performed during these times. RESULTS: The total effective dose received by nursing staff over 7 days was 148 microSv. A nurse working alone for one 8 h shift per day for 7 days could receive an effective dose of 91 microSv. The nursing staff spent an average of 23 min (standard deviation, 15 min) per 8 h shift dealing with the patient. Nursing duties were performed at a contact distance of approximately 0.5 m from the patient. CONCLUSIONS: The nursing contact times required for the management of a helpless patient post-radioiodine therapy are lower than previously estimated. It is possible to successfully treat such a patient whilst keeping the effective doses to nursing staff within appropriate constraints. The measured nursing contact times provide an up-to-date summary of current nursing practice and will be a useful aid in the planning of future treatments.